EIDOSTM is a CE-IVDD certified solution that uses AI to select patients for immunotherapy, a relatively new cancer treatment method that has been around since 2014. The solution is one of the results of the strategic partnership for the use of AI in cancer treatments that Ellogon entered into in 2020 with the Netherlands Cancer Institute (NKI). EIDOSTM is not only effective, but also easy and seamless to integrate into clinical practice.
Ellogon helps determine chances of success
“Unfortunately, immunotherapy is not effective for everyone,” explains Robert Kuipers, CEO of Ellogon: “The result is currently lacking in approximately 30% of the patients who immunotherapy while the therapy would probably benefit from approximately 15% of the unselected patients. Our solution could help to determine the chance of success of immunotherapy for a patient more quickly. This increases the chance of survival for the patient and makes it easier to keep healthcare costs under control.”
Affordable care for everyone
Immunotherapy is currently still very expensive: costs vary from 50,000 to 200,000 euros per patient. The demand for affordable cancer treatments is growing rapidly; the number of cancer cases is expected to increase by 70% over the next twenty years. “ROM InWest is investing in the company because the company is using AI innovations such as EIDOSTM “Digitalization in healthcare is accelerating,” explains Janet Nieboer, CEO ROM InWest. “In doing so, they contribute to sufficient available and affordable healthcare for everyone.”
Immunotherapy popular
Immunotherapy uses the patient's immune system to attack cancer cells in the body, with the aim of preventing the spread of cancer, keeping the cancer under control or eliminating it altogether. The therapy is so popular because it has a three-fold higher chance of overall survival compared to traditional treatments. Many Dutch hospitals now prescribe immunotherapy.
